🔎 Trials Near Me

Início › Linfoma de Burkitt › Illinois

Ensaios clínicos de Linfoma de Burkitt em Illinois

14 estudos para Linfoma de Burkitt estão buscando participantes em locais em Illinois.

Cidades em Illinois

Texto oficial do estudo (Inglês)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e mais 4
RecrutandoFase 2
366 Days – 46 Years · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • e mais 7
RecrutandoFase 3
Idades de 18 a 39 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT03150693

Blinatumomab Consolidation in Real World

  • Northwestern University, Chicago
  • The University of Chicago, Chicago
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e mais 9
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • Advocate Children's Hospital-Oak Lawn, Oak Lawn
  • e mais 3
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e mais 2
RecrutandoFase 2
Idades de 1 a 30 · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e mais 5
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecrutandoFase 2
Idades de 7 a 25 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

  • Research Site, Chicago
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  • Research Site, Chicago
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • University of Chicago Comprehensive Cancer Center, Chicago
RecrutandoFase 2
Idades de 18 a 54 · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

  • University of Chicago Comprehensive Cancer Center, Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 4 de nov. de 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of Chicago, Chicago
RecrutandoFase 1/2
Idades de 15 a 50 · Todos os sexos · Atualizado em 9 de set. de 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Recrutando
Idades de 18 a 50 · Todos os sexos · Atualizado em 19 de jun. de 2025 · NCT06785324

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.